Roopesh Krishnankutty

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Proteasome inhibitors are attractive cancer therapeutic agents because they can regulate apoptosis-related proteins. Bortezomib also known as Velcade®, a proteasome inhibitor that has been approved by the food and drug administration for treatment of patients with multiple myeloma, and many clinical trials are ongoing to examine to the efficacy of(More)
  • 1